MicroPort Scientific Corporation provided unaudited consolidated earnings guidance for the six months ended June 30, 2021. For the six months, the company expected loss attributable to equity shareholders of the Company for the six months ended 30 June 2021 of approximately between USD 90 million and USD 100 million, as compared with a loss of USD 65.6 million for the same period of last year. This change was principally attributable to: (i) the impact of price reduction due to the nationwide centralized procurement policy on coronary stents; (ii) the significant year-on-year increase in expenditures on research and development; (iii) one-time transaction costs of convertible bond issuance. At the same time, the Group achieved double digit year-on-year growth in sales revenue during the reporting period, which partially offset the aforementioned negative impact. Such growth was principally attributable to the significant increase in sales volume of coronary stents driven by the nationwide centralized procurement policy, rapid market penetration, contribution from new product launches, and the increase in elective surgeries from COVID-19 recovery.